## MDT: Medtronic plc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.0% below STRENGTH zone (4.0-10.0%); PEG 2.32 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($97.62)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Cresset Asset Management LLC Sells 16,618 Shares of Medtronic PLC $MDT**
- Source: MarketBeat | 20251206T094139 | Somewhat-Bullish | Relevance: 99%
-  Cresset Asset Management LLC reduced its stake in Medtronic PLC by 8.5% during the 2nd quarter, selling 16,618 shares and retaining 178,873 shares valued at over $15.7 million. Medtronic recently outperformed earnings expectations, reporting $1.36 EPS against an anticipated $1.31, with revenues reaching $8.96 billion. The company also declared a quarterly dividend of $0.71 per share and holds a "Moderate Buy" consensus rating from analysts with an average price target of $110.44.

**2. Medtronic PLC $MDT Shares Sold by Intrepid Family Office LLC**
- Source: MarketBeat | 20251209T140823 | Somewhat-Bullish | Relevance: 99%
-  Intrepid Family Office LLC decreased its stake in Medtronic PLC (NYSE:MDT) by 25% in the second quarter, selling 10,000 shares and retaining 30,000 shares valued at $2.615 million. The medical technology company exceeded quarterly earnings and revenue estimates and announced a quarterly dividend of $0.71 per share. Analysts generally rate Medtronic as a "Moderate Buy" with a consensus price target of $110.44.

**3. Dnca Finance Acquires 14,000 Shares of Medtronic PLC $MDT**
- Source: MarketBeat | 20251208T090835 | Bullish | Relevance: 99%
- Dnca Finance increased its stake in Medtronic PLC by 17.2% in Q2, acquiring an additional 14,000 shares to own a total of 95,550 shares valued at approximately $8.33 million. Medtronic reported strong Q2 earnings, exceeding analyst expectations with $1.36 EPS and $8.96 billion in revenue, and announced a $0.71 quarterly dividend. Analysts currently rate Medtronic as a "Moderate Buy" with an average price target of $110.44.

**4. First Trust Advisors LP Sells 103,019 Shares of Medtronic PLC $MDT**
- Source: MarketBeat | 20251207T111333 | Somewhat-Bullish | Relevance: 99%
-  First Trust Advisors LP reduced its holdings in Medtronic PLC by 10.9%, selling 103,019 shares and retaining 841,814 shares. Medtronic reported stronger-than-expected quarterly earnings and revenue, with FY2026 guidance set at $5.620-$5.660 EPS, and announced a quarterly dividend of $0.71. The stock currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $110.44.

**5. Amundi Purchases 803,584 Shares of Medtronic PLC $MDT**
- Source: MarketBeat | 20251206T080811 | Bullish | Relevance: 98%
-  Amundi significantly increased its stake in Medtronic PLC by 18.8% in Q2, acquiring 803,584 shares to own a total of 5,077,104 shares valued at approximately $448.2 million. Medtronic exceeded earnings expectations with $1.36 EPS and $8.96 billion in revenue, also declaring a quarterly dividend of $0.71, and holds a "Moderate Buy" consensus rating from analysts. Other major institutional investors also adjusted their positions in the medical technology company.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 9, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Barclays | $111 | $109 | +2% |
| 2025-11-20 | Truist Securiti | $110 | $103 | +7% |
| 2025-11-19 | Morgan Stanley | $117 | $107 | +9% |
| 2025-11-19 | RBC Capital | $118 | $111 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Barclays | main | Overweight |
| 2025-11-20 | Truist Securiti | main | Hold |
| 2025-11-19 | Morgan Stanley | main | Overweight |
| 2025-11-19 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.20M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+0.1%)
- Blackrock Inc.: 9.3% (-2.4%)
- JPMORGAN CHASE & CO: 8.1% (+197.7%)
- State Street Corpora: 4.7% (+1.1%)
- Capital Research Glo: 2.4% (-15.6%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.3% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 9 raises (avg +11%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.32 elevated, pricing in significant growth expectations. Forward P/E 16.6x stretched relative to 8% growth. Balance sheet: strong liquidity (2.4x). Analyst sentiment positive (9 raises, avg +11%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $129.9B |
| Beta | 0.72 |
| 52W Range | $79.29 - $106.33 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.32 |
| Forward P/E | 16.6 |
| Current P/E | 17.9 |
| YoY Growth | 8.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.2% to -1.0% (-3.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.0pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.04% (CS: 49) | Neutral |
| RSI_14 | 58.1 | Neutral |
| MACD Histogram | -0.18 | Bearish |
| vs SMA20 | 1.010x | Above |
| vs SMA50 | 1.047x | Above |
| vs SMA200 | 1.115x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $101.26
- **Stop Loss:** $97.62 (3.6% risk)
- **Target:** $104.90 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 137
- **Position Value:** $13,872.62
- **Portfolio %:** 13.87%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-17 (Est: $1.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.31 | $1.36 | +3.5% |
| 2025Q3 | $1.23 | $1.26 | +2.5% |
| 2025Q2 | $1.58 | $1.62 | +2.7% |
| 2025Q1 | $1.36 | $1.39 | +2.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*